Abstract:To the Editor: The use of alternative viral envelope proteins to pseudotype oncoretroviral vectors has contributed substantially to recent improvements in retroviral gene transfer to hematopoietic stem cells. The envelope protein of endogenous feline leukemia virus (RD114) has emerged as a particularly attractive candidate in this context. Initial studies of RD114-pseudotype vectors produced by FLYRD18 packaging cells have shown promise, but it has also been demonstrated that FLYRD18 produces soluble factors that interfere with stem cell maintenance. We hypothesized that novel production methods for RD114-pseudotype vector preparations could overcome this limitation and lead to consistent high-level gene transfer in a canine model of stem cell gene therapy. We have developed a new retroviral packaging cell line based on human 293T cells (Phoenix-RD114). Virally conditioned medium derived from this cell line was volume reduced by centrifugation and resuspension in 1% of the original volume. Here we show that vectors produced by this method led to highly efficient transduction of canine hematopoietic repopulating cells. These results suggest that Phoenix-RD114-derived vectors may allow for more consistent transduction of hematopoietic repopulating cells than FLYRD18-derived vectors. An important obstacle to achieving clinically relevant levels of gene transfer to stem cells has been the low expression of the amphotropic viral receptor on the most immature hematopoietic cell populations1. This has prompted the development of alternative envelope proteins for pseudotyping. The receptor for the feline endogenous retrovirus RD114 is a neutral amino acid transporter that has been shown to be highly expressed on a number of human tissues, including CD34+CD38- hematopoietic cells2. High expression of the receptor for RD114 in these very primitive hematopoietic cells provides a good rationale for the use of the RD114 pseudotype in the context of clinical stem cell gene transfer. Consistent with this rationale, RD114-pseudotype vectors have been shown to transduce efficiently canine hematopoietic repopulating cells3 and human NOD/SCID repopulating cells2,4,5,6. Their stability is a particularly attractive feature of RD114-pseudotype vector particles, allowing for volume reduction by centrifugation2,6. Centrifugation-mediated concentration of vector particles offers two important advantages. First, higher vector titers achieved by centrifugation and resuspension in a smaller volume could potentially lead to higher titers, saturating available receptors on stem cells, thereby overcoming limitations imposed on transduction by low receptor expression1,7,8. Second, the concentration and resuspension significantly deplete potentially unwanted (e.g., FBS) as well as toxic by-products present in the virally conditioned supernatant harvested from producer cell lines. In this context it is important to note that the original RD114-producer cell line, FLYRD18, was reported to have a differentiating activity on repopulating hematopoietic cells4. Production of transduction-inhibiting factors has been described for NIH3T3-derived producer clones9, but not for producer cell lines based on human 293 cells. Recently, we were able to demonstrate an advantage of packaging cell lines derived from human 293T cells (Phoenix-GALV) compared to murine NIH3T3-derived PG13 packaging cells. This combination has led to gene transfer levels of up to 25% in a nonhuman primate model of stem cell gene therapy10. Based on the encouraging results obtained with Phoenix-GALV-producer cells, we established a 293T-based RD114-pseudotype packaging cell line (Phoenix-RD114) in analogy to Phoenix-GALV cells10. We generated a helper-virus-free Phoenix-RD114 producer clone packaging an MGMT(P140K)- and GFP-containing MSCV-based vector (MIEG3Pl40K). Vector-conditioned medium harvested from this clone was volume-reduced by centrifugation (7277g, 4°C for 24 h). Titers were approximately 1.5 107/ml after centrifugation and resuspension in 1% of the original volume. Vector recovery after centrifugation and resuspension was typically 60%, with a range of 37–80%. We exposed the CD34+ cells twice on 2 consecutive days to a 1:10 dilution of concentrated vector for 4 h (effective titer 1.5 106/ml). In vitro gene transfer was comparable to results obtained with unconcentrated high-titer FLYRD18 - derived vector of approximately 10-fold higher titer (0.9–1.5 107)3. However, marking during the early engraftment period was substantially higher using the Phoenix-RD114-derived vector compared to marking in the animals used to evaluated FLYRD18-derived vectors3. Early after transplantation, we observed marking in excess of 30% in all three animals tested (Figs. 1a–1c). As regularly observed after oncoretroviral gene transfer to hematopoietic stem cells, marking levels decreased somewhat in all three dogs and stabilized around day 90 after transplantation at levels of 3 to 19% in granulocytes. Using antibody staining with subset-specific antibodies, we were able to demonstrate marking in granulocytes, monocytes, T cells, and B cells (Fig. 1d). Gene marking was also observed in red blood cells and platelets (Fig. 1e), albeit at somewhat lower levels. Importantly, gene transfer at 3 months in our experience is a reliable predictor of long-term gene marking in dogs. To evaluate gene transfer into human hematopoietic cells with our novel Phoenix-RD114-producer clone, we transduced G-CSF-mobilized peripheral blood CD34+ cells from three different donors using a protocol similar to the one described for the dog studies. The mean gene transfer in three independent experiments was 90% (standard deviation 3%), as determined by flow cytometry, and 72% (standard deviation 5%) in CFU-C as determined by scoring under a fluorescence microscope, demonstrating highly efficient gene transfer. Combining the use of Phoenix-RD114 packaging cells with centrifugation-mediated concentration led to consistent, highly efficient in vivo gene marking in the dog. In fact, our vector production strategy yielded higher and more consistent in vivo gene marking than previous canine stem cell gene therapy studies, including those studies describing gene transfer with FLYRD18-based RD114-pseudotype vectors3, other pseudotypes11,12, or other vector systems such as lentiviral vectors (manuscript submitted). Of note, the effective titer used in this study (1–2 106/ml) was lower than in our previous study using FLYRD18-derived vector, in which higher titers of 5 107 were necessary to achieve gene transfer to canine stem cells. This suggests that further concentration of Phoenix-RD114-derived vector to higher titers could potentially lead to even better in vivo marking. In conclusion, our data show that vectors produced by Phoenix-RD114 allow for efficient transduction of hematopoietic repopulating cells and should be considered in clinical gene therapy applications.

Direct comparison of RD114-pseudotyped versus amphotropic-pseudotyped retroviral vectors for transduction of rhesus macaque long-term repopulating cells.

Sustained multilineage gene persistence and expression in dogs transplanted with CD34(+) marrow cells transduced by RD114-pseudotype oncoretrovirus vectors

Efficient gene transfer to hematopoietic repopulating cells using concentrated RD114-pseudotype vectors produced by human packaging cells.

Long-Term, Clonal Tracking Comparing Autologous Transplantation of G-CSF/SCF-Primed Bone Marrow CD34+ Cells with G-CSF/SCF-Mobilized Peripheral Blood CD34+ Cells in Rhesus Macaques

Comparative study of the transfection efficiency of commonly used viral vectors in rhesus monkey (Macaca mulatta) brains.

Analysis of Origin and Optimization of Expansion and Transduction of Circulating Peripheral Blood Endothelial Progenitor Cells in the Rhesus Macaque Model.

Intra-striatal AAV2.retro administration leads to extensive retrograde transport in the rhesus macaque brain: implications for disease modeling and therapeutic development

Optimized transduction of canine paediatric CD34(+) cells using an MSCV-based bicistronic vector

Generation, expansion, gene delivery, and single-cell profiling in rhesus macaque plasma B cells

Effective and stable gene transduction in rhesus macaque iPSCs capable of T-lineage differentiation utilizing the piggyBac system

The Glymphatic System Delivery Enhances the Transduction Efficiency of AAV1 to Brain Endothelial Cells in Adult Mice.

Long‐term tracking of haematopoietic clonal dynamics and mutations in non‐human primate undergoing transplantation of lentivirally barcoded haematopoietic stem and progenitor cells

Aberrant Clonal Hematopoiesis of the Erythroid and Myeloid Lineages in a Lentivirally Barcoded Rhesus Macaque

Efficient Adenoviral Vector Transduction of Human Hematopoietic Scid-Repopulating and Long-Term Culture-Initiating Cells

Pd-1 Blockade in Rhesus Macaques: Impact on Chronic Infection and Prophylactic Vaccination

Clonal Tracking of Erythropoiesis in Rhesus Macaques

Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates

Clonal Tracking of the Source of Red Cell and Platelet Production in Rhesus Macaques

Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia.

Single-cell cloning of NK cells from rhesus macaques: a new methodology for in-depth analysis of MHC-E-dependent adaptive functions

456. HOXB4 Overexpression Expands Short-Term Repopulating Cells in Nonhuman Primates and Dogs